jeffrey meyerhardt, md, mph, on the implications of the beacon phase 3 study in braf-mutant mcrc
Published 6 years ago • 29 plays • Length 0:39
Download video MP4
Download video MP3
Similar videos
-
1:20
jeffrey a. meyerhardt, md, considers the beacon study in braf mutated metastatic colorectal cancer
-
1:59
scott kopetz, md, phd, facp, on the implications of the beacon phase 3 study in braf-mutant mcrc
-
5:55
colorectal cancer – an introduction, with jeffrey a. meyerhardt, md, mph
-
1:43
jeffrey a. meyerhardt, md, discusses outcomes of the phase 2 study in braf mutated crc patients
-
0:53
jeffrey a. meyerhardt, md discusses the phase 3 calgb/swog 80405 study
-
23:47
what is the cause of cancer?
-
5:23
what you need to know about colorectal cancer
-
21:55
dr christian frezza - mitochondrial dysfunction in cancer
-
0:48
jeffrey meyerhardt, md, mph, discusses the length of adjuvant therapy for colorectal cancer patients
-
0:55
jeffrey meyerhardt, md, mph, considers the addition of vemurafenib to the nccn guidelines for mcrc
-
0:42
jeffrey meyerhardt, md, mph, on dose escalation of regorafenib as a result of the redos study
-
1:05
jeffrey a. meyerhardt, md explains results from the phase 3 calgb/swog 80405 study
-
1:53
jeffrey meyerhardt, md, discusses braf mutation metastatic crc and vemurafenib
-
0:58
stefan kasper, md, provides updates on the beacon trial in braf-mutant crc
-
1:34
jeffrey meyerhardt, md, on how immunotherapies are being studied in gastric & esophageal cancers
-
1:11
jeffrey a. meyerhardt, md weighs in on the economic vs efficacy outcomes in calgb/swog 80405
-
1:02
jeffrey a. meyerhardt, md, on whether regorafenib is becoming more tolerable for mcrc patients
-
1:22
jeffrey a. meyerhardt, md, talks about the dfci wellness study
-
2:56
jeffrey a. meyerhardt, md, talks about the dfci wellness study
-
0:58
jeffrey a. meyerhardt, md explains how os from primary site of tumor may impact treatment
-
1:01
jeffrey a. meyerhardt, md, discusses immunotherapy in msi-stable crc patients
-
1:41
jeffrey a. meyerhardt, md, explains matching mutations and markers to therapies in crc patients
Clip.africa.com - Privacy-policy